Cargando…
Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF
PURPOSE: Vascular endothelial growth factor (VEGF) plays a key role in neovascularization by stimulating the proliferation and migration of vascular endothelial cells. The anti-VEGF therapy bevacizumab acts by binding to VEGF and preventing its effects. However, this linear interaction represents on...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Molecular Vision
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994336/ https://www.ncbi.nlm.nih.gov/pubmed/21139682 |